Related references
Note: Only part of the references are listed.Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine
Jerry L. Jeffrey et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection
Pedro Cahn et al.
AIDS (2022)
Mutations in the HIV-1 3′-Polypurine Tract and Integrase Strand Transfer Inhibitor Resistance
Yuliang Wei et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort study
Barbara Rossetti et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV
Nicholas I. Paton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
High Detection Rate of HIV Drug Resistance Mutations among Patients Who Fail Combined Antiretroviral Therapy in Manaus, Brazil
Yury Oliveira Chaves et al.
BIOMED RESEARCH INTERNATIONAL (2021)
Perspectives on the Barrier to Resistance for Dolutegravir plus Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection
Marta Boffito et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2020)
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
Chloe O. C. Orkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Emergent Resistance to Dolutegravir Among INSTI-Naive Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases
Muge Cevik et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
HIV subtype diversity worldwide
Nicholas Bbosa et al.
CURRENT OPINION IN HIV AND AIDS (2019)
Comparative effectiveness of first-line antiretroviral therapy: results from a large real-world cohort after the implementation of dolutegravir
Mariana Veloso Meireles et al.
AIDS (2019)
Adherence to HIV treatment regimens: systematic literature review and meta-analysis
Frederick Altice et al.
PATIENT PREFERENCE AND ADHERENCE (2019)
Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection
Jessica Radzio-Basu et al.
NATURE COMMUNICATIONS (2019)
Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysis
Mario Cruciani et al.
PLOS ONE (2019)
Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors
Purificacion Cid-Silva et al.
AIDS (2018)
Brazilian network for HIV Drug Resistance Surveillance (HIV-BresNet): a survey of treatment-naive individuals
Monica B. Arruda et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2018)
ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA < 500 000 Copies/mL
Babafemi O. Taiwo et al.
CLINICAL INFECTIOUS DISEASES (2018)
Prevalence of Drug-Resistant Minority Variants in Untreated HIV-1-Infected Individuals With and Those Without Transmitted Drug Resistance Detected by Sanger Sequencing
Dana S. Clutter et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration
Thibault Mesplede et al.
MBIO (2017)
Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial
Ingeborg Wijting et al.
LANCET HIV (2017)
Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase
Peter K. Quashie et al.
JOURNAL OF VIROLOGY (2015)
High prevalence of subtype F in newly diagnosed HIV-1 persons in northwest Spain and evidence for impaired treatment response
Berta Pernas et al.
AIDS (2014)
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
Bonaventura Clotet et al.
LANCET (2014)
Determinants of HIV-1 drug resistance in treatment-naive patients and its clinical implications in an antiretroviral treatment program in Cameroon
Alexander Zoufaly et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2014)
Prevalence of transmitted HIV-1 antiretroviral resistance among patients initiating antiretroviral therapy in Brazil: a surveillance study using dried blood spots
Celina M. P. de Moraes Soares et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2014)
Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study
Hans-Juergen Stellbrink et al.
AIDS (2013)
Phenotypic Susceptibility to Antiretrovirals Among Clades C, F, and B/F Recombinant Antiretroviral-Naive HIV Type 1 Strains
Maria Cecilia A. Sucupira et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2013)
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
Pedro Cahn et al.
LANCET (2013)
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
Francois Raffi et al.
LANCET (2013)
Dolutegravir plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection
Sharon L. Walmsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Non-Catalytic Site HIV-1 Integrase Inhibitors Disrupt Core Maturation and Induce a Reverse Transcription Block in Target Cells
Mini Balakrishnan et al.
PLOS ONE (2013)
Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation
Kellie A. Jurado et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Analysis of Transmitted Resistance to Raltegravir and Selective Pressure among HIV-1-Infected Patients on a Failing HAART in Sao Paulo, Brazil
N. P. Mantovani et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2012)
In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
Masanori Kobayashi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation Classes
Vivek Jain et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
The Brazilian Network for HIV-1 Genotyping External Quality Control Assurance Programme
Denise C. F. Souza et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2011)
HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays
Tamara Bar-Magen et al.
AIDS (2010)
HIV Type 1 Antiretroviral Resistance Mutations in Subtypes B, C, and F in the City of Sao Paulo, Brazil
Patricia Munerato et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2010)
Class-sparing regimens for initial treatment of HIV-1 infection
Sharon A. Riddler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
High levels of primary antiretroviral resistance genotypic mutations and B/F recombinants in Santos, Brazil
Maria Cecilia Araripe Sucupira et al.
AIDS PATIENT CARE AND STDS (2007)
Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals
RM Brindeiro et al.
AIDS (2003)
Share Paper
